WallStSmart

Boston Scientific Corp (BSX)vsUSA Rare Earth, Inc. (USAR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 1254556% more annual revenue ($20.61B vs $1.64M). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

USAR

Avoid

21

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.3
Piotroski: 2/9Altman Z: -41.68
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued

Intrinsic value data unavailable for USAR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

USAR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

USAR4 concerns · Avg: 3.8/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : USAR

USAR has a balanced fundamental profile.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : USAR

The primary concerns for USAR are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a mature stock while USAR is a value play — different risk/reward profiles.

USAR carries more volatility with a beta of 2.42 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 21/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

USA Rare Earth, Inc.

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

USA Rare Earth, Inc. engages in mining, processing, and supplying rare earths and other critical minerals. The company is headquartered in Stillwater, Oklahoma.

Want to dig deeper into these stocks?